Recurrent Glioblastoma Treated with Recombinant Poliovirus | Zendy

Annick Desjardins | Zendy; Matthias Gromeier | Zendy; James E. Herndon | Zendy; Nike Beaubier | Zendy; Dani P. Bolognesi | Zendy; Allan H. Friedman | Zendy; Henry S. Friedman | Zendy; Frances McSherry | Zendy; Andrea Muscat | Zendy; Smita K. Nair | Zendy; Katherine B. Peters | Zendy; Dina Randazzo | Zendy; John H. Sampson | Zendy; Gordana Vlahovic | Zendy; W.T.A. Harrison | Zendy; Roger E. McLendon | Zendy; David M. Ashley | Zendy; Darell D. Bigner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Author(s) -

Annick Desjardins,

Matthias Gromeier,

James E. Herndon,

Nike Beaubier,

Dani P. Bolognesi,

Allan H. Friedman,

Henry S. Friedman,

Frances McSherry,

Andrea Muscat,

Smita K. Nair,

Katherine B. Peters,

Dina Randazzo,

John H. Sampson,

Gordana Vlahovic,

W.T.A. Harrison,

Roger E. McLendon,

David M. Ashley,

Darell D. Bigner

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1716435

Subject(s) - medicine , adverse effect , glioma , population , bevacizumab , gastroenterology , surgery , oncology , chemotherapy , cancer research , environmental health

The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO). PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research